Literature DB >> 3947199

Life-threatening cat-scratch disease in an immunocompromised host.

J R Black, D A Herrington, T L Hadfield, D J Wear, A M Margileth, B Shigekawa.   

Abstract

We describe a renal allograft recipient with cat-scratch disease in whom refractory hypotension, severe metabolic acidosis, pulmonary infiltrates, and encephalopathy developed. The patient first presented with a history of cat bites and scratches, fever, headache, and arthralgias. Four weeks later, the clinical presentation of septic shock suddenly developed in the patient. Cat-scratch disease was documented clinically and by finding delicate pleomorphic bacilli in Warthin-Starry silver stains of biopsy specimens taken from the primary inoculation site and regional lymph node. The administration of intravenous sulfamethoxazole and trimethoprim, erythromycin lactobionate, and tobramycin sulfate therapy correlated with recovery. Although cat-scratch disease is usually a benign, self-limited illness, this article illustrates its systemic nature, its potential for devastating complications in the immunocompromised host, and its possible response to vigorous antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947199

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

1.  Treatment of adult systemic cat scratch disease with gentamicin sulfate.

Authors:  D E Lewis; M R Wallace
Journal:  West J Med       Date:  1991-03

Review 2.  Unraveling mysteries associated with cat-scratch disease, bacillary angiomatosis, and related syndromes.

Authors:  R Regnery; J Tappero
Journal:  Emerg Infect Dis       Date:  1995 Jan-Mar       Impact factor: 6.883

3.  Intracellular growth of Afipia felis, a putative etiologic agent of cat scratch disease.

Authors:  K A Birkness; V G George; E H White; D S Stephens; F D Quinn
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

Review 4.  Cat scratch disease during infliximab therapy: a case report and literature review.

Authors:  Yi Zhou; Geng Yin; Chunyu Tan; Yi Liu
Journal:  Rheumatol Int       Date:  2014-12-30       Impact factor: 2.631

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.